Zimmer Biomet Holdings, Inc. (ZBH)
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates; full-year EPS guidance raised on strong segment growth.
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.01 per share a year ago.
Zimmer Biomet raises annual profit forecast on strong demand for medical devices
Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants.
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
